Archive for the ‘stem cell therapy’ Category

New Hearts To Be Grown From Stem Cells

Wednesday, October 2nd, 2013

By Ronda Wendler, Texas Medical Center News 

Building natural organs from stem cells is the way forward in regenerative medicine.

Building natural organs from stem cells is the way forward in regenerative medicine.

The Texas Heart Institute and the veterinary medicine college at Texas A&M University will share a $3 million award from the state of Texas’ Emerging Technology Fund to create the Center for Cell and Organ Biotechnology.

“This center will play a key role in securing Texas’ very critical emerging role in biotechnology,” Gov. Rick Perry said at a Press Conference at the Heart Institute. “The sky is truly the limit for what this center will be able to accomplish.”

The new collaboration will focus on cell therapies and regenerative medicine, including building natural organs from stem cells.

Doris Taylor, Ph.D., who in 2008 created a beating rat heart at the University of Minnesota, was recruited to the Texas Heart Institute last year and will head the new center.

“Dr. Taylor is certainly one of the stars in the adult human stem cell field, and we feel extremely fortunate to have her,” said James Willerson, M.D., the Texas Heart Institute’s president and medical director.

Taylor is the developer of a technique known as decellularization, which involves stripping cells from an animal heart, leaving only a shell or scaffold of the heart in place, then infusing the scaffold with human stem cells to grow a new human heart.

At the Heart Institute, Taylor has created human heart models that are currently functioning at one-fourth capacity. She hopes to engineer a heart that functions at close to 100 percent capacity by 2015. The goal is to test such bioengineered hearts in clinical trials, probably in less than 10 years, she said, and eventually offer a solution to patients waiting for donor hearts, which are always in short supply.

Other scientists around the world are striving to do the same, and Texas Heart Institute founder Denton Cooley, M.D., said during the press conference that successful culmination of the institute’s efforts to engineer a human heart would be a fitting continuation of the heart institute’s legacy.

The decellularization approach is also being tried with other organs, Taylor said, including livers, kidneys and lungs.

Texas A&M’s College of Veterinary Medicine and Biomedical Sciences will contribute animal disease models to be used in cell therapy trials, as well as bioengineers who will build scaffolding upon which heart cells will grow. and experts in anatomy, physiology and stem cell science.

Scientists from the Heart Institute and Veterinary College will collaborate not only to grow new organs, but also to detect diseases earlier and to devise new cell and gene therapies to help prevent and treat diseases and injuries.

Texas A&M has more than 20,000 veterinary cases a year of animals with disease, and therefore will be invaluable in providing animals that can contribute to and benefit from this research, Taylor said.

Veterinarians and Heart Institute scientists will collaborate in other ways as well, she said. For example, racehorses with tendonitis are already being treated with stem cell therapy, and lessons learned could help human athletes. Doberman Pinschers routinely get heart disease and could benefit from the regenerative medicine efforts underway at the heart institute.

“It was clear from the beginning that this partnership was special,” said Eleanor Green, D.V.M., dean of A&M’s College of Veterinary Medicine and Biomedical Sciences. “We know that the health of animals and people is inextricably linked, and this unique center will advance both human and animal health.”

The state of Texas’ Emerging Technology Fund that funds the new center is a technology investment fund created at the urging of Gov. Rick Perry to give Texas an advantage in developing and commercializing emerging technologies. Launched in 2005, the fund has given out more than $200 million to startup companies and educational institutions.

The Texas Heart Institute’s next step, Taylor said, is to hire a technology transfer expert who will help form spin-off companies and commercialize its inventions.

 

Adult Stem Cells Aid Blood Cell Recovery

Saturday, July 27th, 2013

As reported By Katherine Kallergis – MiamiHerald.com 

IV Drip

 

“Today is my second birthday,” said George Schwartz, 70.

Schwartz was celebrating after undergoing an adult blood stem cell transplant at the University of Miami’s Sylvester Comprehensive Cancer Center about 10 days ago. Schwartz had been diagnosed with multiple myeloma, a cancer that targets the blood cells in the bone marrow, about a year and a half ago.

Adult blood stem cell transplants allow for healthy blood cell production after a patient receives high doses of chemotherapy.

“I got a second chance of life back,” Schwartz said, hours after his transplant. He was the 200th patient to receive a transplant in the 2-year-old inpatient unit.

The Adult Stem Cell Transplant Program at Sylvester treats people with acute and chronic leukemia and multiple myeloma, cancers of the blood. In multiple myeloma, abnormal plasma cells called myeloma cells multiply in the bone marrow. When the cancerous cells multiply, the result is fewer healthy blood cells: red blood cells, white blood cells and platelets.

Dr. Krishna Komanduri, director of UM’s Adult Stem Cell Transplant program, has directed the program, established in 1992, since 2008. Before that, he spent nearly a decade at M.D. Anderson Cancer Center in Houston.

At Sylvester, Komanduri works to find novel therapies and transplants.

“Blood stem cell transplants are the preferred therapy,” he said, stressing the program does not work with embryonic stem cells, but adult stem cells.

Adult blood stem cells are coaxed out of a patient’s or donor’s bone marrow into the bloodstream with medication, and then are removed. Once the stem cells have been removed from the body, the patient can receive high doses of chemotherapy, without destroying the stem cells.

After the chemo has worn off, the stem cells are transfused back into the patient through an IV, which allows the bone marrow’s blood cell production to recover more quickly.

There are two types of transplants: Allogeneic transplants use donor cells, while autologous transplants use the patient’s own cells.

Positive outcomes for donor transplants have increased significantly, Komanduri said. One-year survival rates for the most common leukemia treated with allogeneic, or donor, transplants are now more than 70 percent. Deaths in these circumstances have dropped from more than 30 percent to around 10 percent.

That statistic doesn’t take into account older patients who would have been excluded in the past, such as Schwartz. Today, they’re being treated and surviving.

In addition, the risk of dying after an autologous transplant like the one Schwartz received has dropped from 5 to 10 percent to around 1 percent, Komanduri said.

Komanduri’s research focuses on T cells, a type of white blood cell that coordinates an immune response. He focuses on how the T cells function in healthy individuals and in stem cell transplant recipients. He’s particularly interested in why the transplanted donor cells can sometimes attack the recipient’s body.

Idania Diaz, who was the program’s 100th patient, received her transplant nine months ago.

Diaz, 60, was diagnosed with multiple myeloma around January 2012 and was treated at the inpatient unit in October 2012. She said she was devastated when she was diagnosed, but Komanduri explained everything to her.

“He told me the good, the bad and the ugly,” Diaz said. “But I had to decide whether I was going to do the transplant.”

Diaz, a third-grade teacher at Fienberg-Fisher K-8 Center in Miami Beach, was in the hospital for two weeks after the transplant and then confined to her home for a couple of months to reduce the chance of infection.

She was able to return to work this April.

“To be able to leave your job and come back as if you’d never left is great,” she said. “I’m back to my normal, healthy lifestyle. I’m happy.”

 Read more here: http://www.miamiherald.com/2013/07/26/3524370/stem-cell-transplant-aids-blood.html#storylink=cpy